Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Leuk Lymphoma. 2017 Oct 25;59(7):1700–1709. doi: 10.1080/10428194.2017.1390230

Figure 2. Cost-effectiveness acceptability curves at various survival benefit levels for germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes.

Figure 2

Subtype-based treatment is based on gene expression profiling (GEP) assay. (A) Minimal survival improvement for both subtypes by novel treatment, (B) modest survival improvement only for ABC subtype by novel treatment, (C) modest survival improvement for both subtypes by novel treatment.